WeightWatchers to Provide Novo Nordisk's Oral Wegovy Pending Approval Next Year | PharmExec

WeightWatchers to Provide Novo Nordisk's Oral Wegovy Pending Approval

WeightWatchers is positioning itself to compete in the rapidly evolving weight-loss drug market, which is being driven by affordability and accessibility, as the FDA fast-tracks GLP-1 treatments under its new pilot National Priority Voucher program.

According to Reuters, WeightWatchers plans to offer Novo Nordisk's oral version of Wegovy if it receives FDA approval and debuts in the US next year.

In a competitive landscape of telehealth companies offering weight management drugs in microdoses, WeightWatchers aims to differentiate itself in a market with increasing competition.

Tara Comonte, the company's CEO, told Reuters, "We have been working with Novo Nordisk ahead of time to support the launch of oral weight-loss medication." She added, "A lot of people don't want an injection. And the convenience of a pill is going to be huge."

FDA's National Priority Voucher Program

This development occurs as Eli Lilly and Novo Nordisk gain momentum. The FDA recently added Orforglipron and Wegovy to the Commissioner's National Priority Voucher (CNPV) program, expanding the initiative to 15 products addressing public health and national security priorities.

The pilot CNPV program allows qualifying sponsors to obtain a voucher, enabling the FDA to complete its review in as little as one to two months, compared to the typical 10-12-month review period following final submission.

According to a press release, national priority vouchers are granted to products where the company has agreed to increase affordability, domesticate manufacturing as a national security issue, or address an unmet public health need.

Previously stated in June, a common-sense approach will allow companies to submit the majority of the drug application before a clinical trial is complete so inefficiencies can be reduced. The ultimate goal is to bring more cures and meaningful treatments to the American public.

Impact on Affordability

GLP-1s will be included in TrumpRx (the administration's direct purchasing platform), making anti-obesity medications from Lilly and Novo available to patients with Medicaid or Medicare. This includes current medications and the oral versions, further increasing affordability.

Medicare patients will have a $50 copay for injectable GLP-1s. Reportedly, oral GLP-1 medications from Eli Lilly and Novo will be available on the government-run DTC platform for $145 per month, matching the price through Medicare and Medicaid. Health tracking apps like Shotlee can help monitor the effects of these medications.

WeightWatchers argues that these lower prices provide an opportunity to retain customers, compared to telehealth competitors, given HCPs anticipate that patients will switch back to the branded drugs following the voucher announcement.